Foundation Fighting Blindness, a world leader in retinal research funding, will feature nearly 100 posters and presentations on its: global patient registry, ProgStar natural history study for Stargardt disease, patient genetic testing program, and dozens of FFB-funded basic and translational research efforts. Its pre-ARVO Retinal Innovation Summit is sold out.
Notable industry executive brings more than 15 years of ophthalmic experience and award winning achievement to FFB’s mission.
Jason Morris, Chief Administrative Officer at TKC Holdings, has been appointed to the Foundation Fighting Blindness Board of Directors, the Foundation announced today.
Today’s U.S. Food and Drug Administration (FDA) approval of voretigene neparvovec, to be marketed as LUXTURNA, will be life-changing for patients with vision loss due to mutations in the RPE65 gene and a watershed moment for the inherited retinal disease field, says the Foundation Fighting Blindness.
The Foundation Fighting Blindness (FFB), the world’s leading private funder of research on treatments and cures for vision-robbing inherited retinal diseases, strongly opposes recent U.S. Senate and House of Representatives actions which would slow or stop research on treatments for Americans impacted by rare diseases.
The Foundation Fighting Blindness (FFB) announced that it has selected Benjamin Yerxa, a biotechnology and drug development executive, as its Chief Executive Officer, effective immediately.
Approval of the gene therapy will allow treatment for people with vision-loss due to RPE65 mutations and will help advance other investigational studies with potential to help millions, FFB tells the Committee.
The Foundation Fighting Blindness (FFB), the world’s leading private funder of research on preventions, treatments and cures for vision loss due to inherited retinal diseases is accepting applications for its next round of funding grants to be awarded May 2018.
The first patient has been enrolled in a four-year natural history study of people with mutations in the USH2A gene.
The National Center for Excellence in Fighting Blindness, a Gund-Harrington Initiative, has opened its fourth annual Gund-Harrington Scholar Award competition to support innovative research efforts that seek to prevent, treat or cure blindness.